MUHAMMAD SHABBIR: Open Payments
NPI 1285879338 · MERCED, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$499 in 23 payments from 12 companies in 2025. Trend: 2023 $364 · 2024 $602 · 2025 $499
Food & beverage: $499
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 5 | $90 |
| Novo Nordisk Inc | 3 | $83 |
| AstraZeneca Pharmaceuticals LP | 3 | $54 |
| Exact Sciences Corporation | 2 | $48 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $47 |
| Lilly USA, LLC | 2 | $40 |
| ABIOMED | 1 | $26 |
| Abbott Laboratories | 1 | $24 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $23 |
| Corcept Therapeutics | 1 | $23 |
Products named: SHINGRIX, Cologuard Collection Kit, CAPLYTA, MOUNJARO, BREZTRI, Rybelsus, TRELEGY ELLIPTA, Ozempic.
Industry payments across CA — which companies pay providers there.
